In the last week of December, while most of the U.S. was still in holiday mode, Novo Nordisk’s plant in North Carolina was operating at full capacity.
On Dec. 22, the U.S. Food and Drug Administration (FDA) approved the company’s oral version of Wegovy, making it the first pill of the popular GLP-1 medications to get the green light for weight loss. People who want to lose weight and are prescribed Wegovy now have the option of taking the tablet daily, versus injecting themselves with the drug once a week. They’ll lose about the same amount of weight with either version: between 16% and 17% of their starting body weight.
